Michael Forbes, CEO of Adastra, claimed in his initial press release: “Hurt reduction is often a critically critical and mainstream matter, and we are being on the forefront of drug rules through the board.” “We're going to Examine how the commercialization of this material fits in with our business enterprise model at Adastra in order to